Coherus Oncology (CHRS) Non Operating Interest Expenses (2013 - 2026)

Coherus Oncology has disclosed Non Operating Interest Expenses across 14 years of filings, most recently posting $2.3 million for Q2 2026.

• In Q2 2026, Non Operating Interest Expenses rose 2.02% year-over-year to $2.3 million; the TTM figure through Jun 2026 stood at $9.1 million (down 0.91% YoY), while the FY2025 annual figure was $9.0 million, down 16.14% from the prior year.
• Non Operating Interest Expenses came in at $2.3 million for Q2 2026 at Coherus Oncology, up from $2.2 million in the prior quarter.
• In the past five years, Non Operating Interest Expenses ranged from a high of $10.6 million in Q4 2023 to a low of $1.9 million in Q4 2024.
• Average Non Operating Interest Expenses over 5 years is $5.5 million, with a median of $3.6 million recorded in 2024.
• Year-over-year, Non Operating Interest Expenses surged 62.01% in 2022 and tumbled 81.99% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $9.4 million in 2022, then grew by 13.15% to $10.6 million in 2023, then plunged by 81.99% to $1.9 million in 2024, then advanced by 17.63% to $2.2 million in 2025, then increased by 3.29% to $2.3 million in 2026.
• Per Business Quant data, the three most recent Non Operating Interest Expenses figures were $2.3 million in Q2 2026, $2.2 million in Q1 2026, and $2.2 million in Q4 2025.